Telix Pharmaceuticals (Telix Pharmaceuticals) Debt-to-Equity : 0.12 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals Debt-to-Equity?

Telix Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.0 Mil. Telix Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10.6 Mil. Telix Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $99.7 Mil. Telix Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Telix Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

TLPPF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.03 Max: 1.18
Current: 0.12

During the past 9 years, the highest Debt-to-Equity Ratio of Telix Pharmaceuticals was 1.18. The lowest was 0.01. And the median was 0.03.

TLPPF's Debt-to-Equity is ranked better than
55.59% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs TLPPF: 0.12

Telix Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Telix Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Debt-to-Equity Chart

Telix Pharmaceuticals Annual Data

Trend

Sep99

Sep00

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

1.18

0.13

0.12

Telix Pharmaceuticals Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial								1.18	0.02	0.13	0.17	0.12

Competitive Comparison of Telix Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Telix Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telix Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's Debt-to-Equity falls into.

Telix Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Telix Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.044	+	10.633)	/	99.673
	=	0.12

Telix Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.044	+	10.633)	/	99.673
	=	0.12

Telix Pharmaceuticals (OTCPK:TLPPF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Telix Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals (Telix Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

TLX:Australia

Address

55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051

Website

https://www.telixpharma.com

Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.